GLYCINE- glycine irrigant 
B. Braun Medical Inc.

----------

1.5% Glycine Irrigation USP

DESCRIPTION

Each 100 mL contains:

Glycine USP ..................................................................................... 1.5 g
Water for Injection USP ...................................................................     qs

pH: 6.1 (4.5-6.5)
Calculated Osmolarity: 200 mOsmol/liter

The formula of the active ingredient is:

IngredientMolecular FormulaMolecular Weight
  Glycine USP  NH2CH2COOH  75.07

1.5% Glycine Irrigation USP is a sterile, nonpyrogenic aqueous solution suitable for urologic irrigation. This solution is slightly hypotonic.

The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

Not made with natural rubber latex, PVC or DEHP.

CLINICAL PHARMACOLOGY

1.5% Glycine Irrigation USP is nontoxic and nonhemolytic with a refractive index close to that of water. These properties make it useful as a urologic irrigating fluid, particularly during transurethral surgical procedures where the irrigant may be absorbed through cut venous sinuses.

Systemically absorbed glycine is primarily metabolized by transamination to serine, and by deamination to ammonia which is normally removed by its conversion to urea. A portion of the absorbed glycine is excreted by the kidneys.

INDICATIONS AND USAGE

1.5% Glycine Irrigation USP is indicated as an irrigant during transurethral prostatic or bladder surgery.

CONTRAINDICATIONS

1.5% Glycine Irrigation USP is not for injection. It is contraindicated in patients with anuria.

WARNINGS

Solutions for urologic irrigation must be used with caution in patients with severe cardiopulmonary or renal dysfunction.

The amount of fluid absorbed during a transurethral resection is a function of the volume and hydrostatic pressure of the irrigant used, the number and size of venous sinuses opened, and the duration of the procedure. Since irrigating fluids used during transurethral prostatectomy have been demonstrated to enter the systemic circulation in relatively large volumes, any irrigation solution must be regarded as a systemic drug.

Absorption of large amounts of fluids containing glycine and the resultant osmotic diuresis may significantly affect cardiopulmonary and renal dynamics. Absorption of large amounts of irrigating solution can also result in pronounced hyponatremia and water intoxication.

After opening container, the contents should be used promptly to minimize the possibility of bacterial growth or pyrogen formation.

Discard unused portion of irrigating solution since it contains no preservative.

PRECAUTIONS

Cardiovascular status, especially in patients with cardiac disease, should be carefully determined before and during transurethral resection of the prostate when using 1.5% Glycine Irrigation USP as an irrigant. The fluid absorbed into the systemic circulation via severed prostatic veins may produce significant extracellular fluid expansion and lead to fulminating congestive heart failure.

Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of 1.5% Glycine Irrigation USP may lower serum sodium concentration and aggravate pre-existing hyponatremia.

Excessive loss of water and electrolytes may lead to serious imbalances. Sustained diuresis from transurethral irrigation with 1.5% Glycine Irrigation USP may obscure and intensify inadequate hydration or hypovolemia.

Care should be exercised if impaired liver function is known or suspected. Under such conditions, ammonia resulting from the metabolism of glycine may accumulate in the blood.

Use only if solution is clear and container and seal are intact.

ADVERSE REACTIONS

Adverse reactions may include fluid and electrolyte disorders such as acidosis, electrolyte loss, marked diuresis, urinary retention, edema and dehydration; cardiovascular/pulmonary disorders such as pulmonary congestion, hypotension, tachycardia, angina-like pain and thrombophlebitis; other possible reactions include visual disturbances, convulsions, nausea, vomiting, diarrhea, vertigo and urticaria.

Literature includes reports on hyponatremia, hyperammonemia, transient blindness, coma (immediate or delayed), and digitalis toxicity in digitalized patients.

If an adverse reaction occurs, discontinue the irrigant and reevaluate the clinical status of the patient.

DOSAGE AND ADMINISTRATION

As required for irrigation.

1.5% Glycine Irrigation USP should be administered only by the appropriate transurethraI urologic instrumentation.

It has been reported that absorption is significantly increased if the container is higher than 60 cm (24 inches) above the patient.

This drug product should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

1.5% Glycine Irrigation USP is supplied sterile and nonpyrogenic in single-dose 3000 mL flexible irrigation containers packaged 4 per case.

NDCREFSize
0264-7390-60R84063000 mL

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.

Do not warm container over 150°F (66°C).

Rx only

Revised: October 2015

Instructions for Preparation and Administration

For Irrigation Use Only.

Not for injection.

Not for use with pressurized irrigation systems or powered irrigation devices.

Aseptic technique is required.

Tear Notches, Overwrap illustration

1.     To open: Tear overwrap starting from the tear notches. (Figure 1)

Figure 1 illustration

2.     Prepare medication port by removal of aluminum foil. (Figure 2a)

Figure 2 illustration
Figure 3 illustration

3.      Remove aluminum foil from outlet/set port at the bottom of container (Figure 4a) and attach administration set (Figure 4b): use non-vented infusion set or close air vent on a vented set. Refer to directions for use accompanying the administration set.

Figure 4 illustration

4.        Hang bag on IV Pole. (Figure 5)

Figure 5 illustration

B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862

Y36-002-909   LD-412-4

PRINCIPAL DISPLAY PANEL - 3000 mL

1.5% Glycine
Irrigation USP

For Urologic Irrigation

REF R8406
NDC 0264-7390-60
LOT
EXP.

3000 mL

Each 100 mL contains:
Glycine USP 1.5 g
Water for Injection USP qs

pH: 6.1 (4.5-6.5)

Calc. Osmolarity: 200 mOsmol/liter

Not for Injection.

Use only if solution is clear and container and seal are
intact.

Warning: Do not warm container over 150°F (66°C).

Sterile, nonpyrogenic. Single unit container. Discard
unused portion. Use aseptic technique.

Recommended Storage: Room temperature (25°C).
Avoid excessive heat. Protect from freezing.
Do not remove overwrap until ready for use.
See Package Insert.

Not made with natural
rubber latex, PVC or DEHP.    

Rx only

recycle symbol

 

 

 

SET

 set picture

B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862

Y38-000-045     LD-257-5

UNIT LABEL
GLYCINE 
glycine irrigant
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0264-7390
Route of AdministrationIRRIGATION
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
GLYCINE (UNII: TE7660XO1C) (GLYCINE - UNII:TE7660XO1C) GLYCINE1.5 g  in 100 mL
Inactive Ingredients
Ingredient NameStrength
WATER (UNII: 059QF0KO0R)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0264-7390-604 in 1 CASE12/04/2013
13000 mL in 1 CONTAINER; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01678412/04/2013
Labeler - B. Braun Medical Inc. (002397347)

Revised: 1/2019
Document Id: f1b2e399-22a3-4567-a07e-ff45b9c6dc12
Set id: f4d83550-42de-44c7-b8d5-1d0debc6aec2
Version: 6
Effective Time: 20190107
 
B. Braun Medical Inc.